Diagnostic and treatment hurdles in plasma cell myeloma with t(11;14) translocation: A case report
Shun Yin Kong, WK Lam, Ka Shu Li, Ka Pik Vivian Yeung, Chung Yin Ha, Ho Kei Lai, Hay Nun Chan, Yiu Ming Yeung, Sze Fai Yip
Abstract
Open-access reader
Shun Yin Kong, WK Lam, Ka Shu Li, Ka Pik Vivian Yeung, Chung Yin Ha, Ho Kei Lai, Hay Nun Chan, Yiu Ming Yeung, Sze Fai Yip
Abstract
Open-access reader
t(11;14) translocation is one of the most common chromosomal abnormalities in plasma cell myeloma. The present case report presented a case of plasma cell myeloma with t(11;14) translocation, in which the plasma cells were small lymphoplasmacytoids in morphology with positive cluster of differentiation-20 and Cyclin D1 expression. These results led to initial diagnostic difficulties. The patient was refractory to bortezomib-based therapy, and responsive to vincristine, doxorubicin and dexamethasone. However, the prognostic value of t(11;14) in plasma cell myeloma remains to be determined. With recent advances in treatment options, physicians should be aware of the clinical and pathological characteristics of this translocation in plasma cell myeloma.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
t(11;14) translocation is one of the most common chromosomal abnormalities in plasma cell myeloma. The present case report presented a case of plasma cell myeloma with t(11;14) translocation, in which the plasma cells were small lymphoplasmacytoids in morphology with positive cluster of differentiation-20 and Cyclin D1 expression. These results led to initial diagnostic difficulties. The patient was refractory to bortezomib-based therapy, and responsive to vincristine, doxorubicin and dexamethasone. However, the prognostic value of t(11;14) in plasma cell myeloma remains to be determined. With recent advances in treatment options, physicians should be aware of the clinical and pathological characteristics of this translocation in plasma cell myeloma.
Key concepts: Plasma Cell Myeloma, Multiple myeloma, Chromosomal translocation, Bortezomib, Plasma cell leukemia, Plasma cell, Cancer research, Plasma cell neoplasm